tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Xbrane Biopharma Strengthens Financial Position and Advances Biosimilar Portfolio

Story Highlights
  • Xbrane Biopharma reported significant revenue growth and profitability in 2025.
  • The company is advancing its biosimilar portfolio with strategic transactions and regulatory progress.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Xbrane Biopharma Strengthens Financial Position and Advances Biosimilar Portfolio

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Xbrane Biopharma AB ( (SE:XBRANE) ) is now available.

Xbrane Biopharma AB reported a profitable first half of 2025, with significant revenue growth and a strengthened financial position due to strategic transactions and a directed share issue. The company is advancing its biosimilar candidate Lucentis® in the US regulatory process and has initiated a clinical study for Xdivane™, positioning itself for future growth and market expansion.

The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK0.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.

More about Xbrane Biopharma AB

Xbrane Biopharma AB is a biotechnology company specializing in the development and commercialization of biosimilars. The company’s primary focus is on providing cost-effective biological drugs, with a significant presence in the European market and ongoing regulatory processes in the US.

Average Trading Volume: 14,768,446

Technical Sentiment Signal: Sell

Current Market Cap: SEK438.2M

For detailed information about XBRANE stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1